SAN RAMON, Calif.--(BUSINESS WIRE)--BioVentrix, Inc., developer of the first transcatheter device for left ventricular remodeling after a heart attack, today announced it received renewal of the ...
91 German Hospitals Now Eligible to Negotiate Full Coverage for Revivent Therapy Our team has successfully secured full reimbursement in Germany. Obtaining NUB Status 1a again for 2026 is an important ...
SAN RAMON, Calif.--(BUSINESS WIRE)--BioVentrix, Inc., a privately-held company with a first-in-class, transcatheter-based structural heart device to treat heart failure, today announced that the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results